Skip to content
    CHE
    Earnings call· Jun 2026(Q2 FY26)

    CHEMED Q2 FY26 earnings call CHE

    Jul 29, 2026 Source

    Executive summary

    Chemed Q2 FY26 — VITAS Outperforms, Roto-Rooter Navigates Marketing Headwinds

    Chemed delivered a strong second quarter, primarily driven by VITAS's significant outperformance in admissions and margin expansion, leading to raised full-year guidance. Roto-Rooter demonstrated solid commercial growth and improved water restoration collections, though it continued to navigate challenges from increased internet marketing costs and a decline in independent contractor revenue. The company remains focused on strategic franchise acquisitions for Roto-Rooter and sustainable growth for VITAS, leveraging its strong cash flow and low leverage.

    Highlights

    6
    • VITAS average daily census (ADC) increased 6.1% year-over-year, exceeding 24,000 patients for the first time.

    • VITAS admissions increased 9% year-over-year to 19,125, driven by both hospital and non-hospital sources.

    • VITAS added $8.9 million to its Medicare cap cushion in the Florida combined program during the quarter.

    • VITAS adjusted EBITDA (excluding Medicare Cap) increased 20.6% year-over-year to $80.6 million.

    • Total Chemed revenue increased 8.8% and adjusted diluted EPS increased 41.9% in Q2 2026 compared to Q2 2025.

    • Roto-Rooter commercial revenue increased 6.8% year-over-year, with branches having commercial business managers seeing a 13% increase.

    Concerns

    4
    • Roto-Rooter's marketing spend increased by $3.1 million year-over-year due to a higher proportion of paid leads (59% of total leads vs. 54% in Q2 2025).

    • Roto-Rooter's independent contractor revenue declined 1.9% in the quarter.

    • Roto-Rooter's water restoration revenue declined 6.7% and average revenue per job declined 3.5% due to billing centralization disruption.

    • Roto-Rooter's adjusted EBITDA margin declined 77 basis points year-over-year to 21.1%.

    Guidance & targets

    10
    CategoryTargetConfidence
    VITAS Full-year ADC growth
    5.75% to 6.25%
    high materiality
    High
    VITAS Full-year revenue growth (excluding Medicare Cap)
    8.25% to 9.25%
    high materiality
    High
    VITAS Full-year EBITDA margin (excluding Medicare Cap)
    19% to 19.5%
    high materiality
    High
    VITAS Full-year Medicare Cap billing limitation
    $7 million
    medium materiality
    High
    Roto-Rooter Full-year revenue growth
    3% to 3.5%
    medium materiality
    High
    Roto-Rooter Full-year adjusted EBITDA margin
    21.5% to 22.5%
    medium materiality
    High
    Full-year 2026 adjusted diluted EPS
    $25 to $25.75
    high materiality
    High
    Full-year 2026 effective corporate tax rate on adjusted earnings
    24.5%
    low materiality
    High
    Full-year 2026 diluted share count
    13.5 million shares
    low materiality
    High
    Medicare Cap billing limitation
    $9.5 million
    medium materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    VITAS
    VITAS performance exceeded expectations, driven by strong admissions and effective management of the Medicare Cap. The segment returned to a normalized growth rate, with ADC exceeding 24,000 patients for the first time. Staffing levels were maintained below budgeted targets without impacting growth expectations.
    Average Daily Census (ADC): 23,687 patientsADC growth: 6.1%Total patient census: exceeded 24,000Admissions: 19,125Admissions growth: 9% YoYHospital admissions as % of total (Florida combined program): 42.9%Admissions from other preadmission locations (Florida combined program) growth: 8.1% YoYMedicare Cap billing limitation accrued: $0.5 million (California)Medicare Cap billing limitation (Florida combined program): $0Average revenue per patient day: $209.98Average revenue per patient day growth: 143 bps YoYHigh acuity days of care as % of total: 2.2%High acuity days of care decline: 24 bps YoYAdjusted EBITDA (excluding Medicare Cap) growth: 20.6% YoYAdjusted EBITDA margin (excluding Medicare Cap): 18.2%Average length of stay: 101.2 days (vs 137.1 days in Q2 2025)Median length of stay: 16 days (vs 20 days in Q2 2025)New starts (Marion, Pasco, Pinellas counties) admissions: 594 in Q2 2026
    $443.3 million11.9%$80.6 million (Adjusted EBITDA ex-Cap)
    Roto-Rooter
    Roto-Rooter performed in line with expectations, with strong commercial revenue growth driven by its business manager program. Water restoration collections improved, but the segment faced headwinds from increased internet marketing costs and declining independent contractor revenue, leading to a slight decline in adjusted EBITDA margin.
    Branch commercial revenue: $56.8 millionBranch commercial revenue growth: 6.8% YoYCommercial revenue increase in branches with commercial business managers: 13%Commercial revenue decline in branches without commercial business managers: 1%Branch residential revenue: $159.1 millionBranch residential revenue growth: 1.7% YoYWater restoration revenue decline: 6.7%Independent contractor revenue decline: 1.9%Adjusted EBITDA growth: essentially flat YoYAdjusted EBITDA margin: 21.1%Adjusted EBITDA margin decline: 77 bps YoYGross margin: 50.4%Gross margin improvement: 135 bps YoYTotal water restoration write-offs improved: $1.3 millionWater restoration employees reduced: 20Average revenue for water restoration job decline: 3.5% (sequential improvement from 13% in Q1 2026)Total leads decline: 1.6% YoYInternet search leads decline: 13.1%Paid leads increase: 7.3%Paid leads as % of total: 59% (vs 54% in Q2 2025)Marketing spend increase: $3.1 million YoY
    $48.5 million (Adjusted EBITDA)

    Operational metrics

    3
    Total Chemed revenue growth
    8.8%YoY
    Q2 FY26

    Combination of VITAS and Roto-Rooter business units.

    VITAS full-time equivalents (FTEs)
    below budgeted targets
    Q2 FY26

    Current staffing level does not impede growth expectations or ability to hire/retain caregivers.

    Hospice rate update (proposed rule for 2027)
    2.4%
    FY27

    Based on current mix in Florida. Final rule expected in a couple of weeks.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trends101.2 daysdays
    Membership covered lives by line23,687patients
    Segment revenue operating income$443.3 millionUSD
    Adjusted EPS EBITDA leverage guidance$25 to $25.75USD

    Deals & partnerships

    2
    Roto-Rooter franchises in South Texas (including Corpus Christi)Purchase of territory and assets$12 million

    This territory will be an independent contractor and represents a significant new population base. Transcription note: 'billion' in transcript corrected to 'million' based on context of Roto-Rooter franchise values.

    4 Roto-Rooter franchisesRepurchasing franchises in strategically advantageous locations$33.5 million

    Aggregate spend through the first 6 months of 2026. Company intends to continue taking advantage of such opportunities. Transcription note: 'billion' in transcript corrected to 'million' based on context of Roto-Rooter franchise values.

    Risks & headwinds

    5
    Increased Internet marketing costs for Roto-RooterQ2 FY26, ongoing

    $3.1 million increase YoY; 59% of total leads were paid (vs 54% in Q2 2025)

    Mitigation: Diversifying lead generation through commercial business managers and app development; leveraging ancillary services to make paid leads profitable.

    Challenges in Roto-Rooter's independent contractor businessQ2 FY26, ongoing

    Revenue declined 1.9% in Q2 FY26

    Mitigation: Actively working with the contractor group to help mitigate challenges and return to a growth trajectory.

    Disruption from water restoration billing centralizationQ2 FY26, expected to improve as year progresses

    Average revenue per water restoration job declined 3.5% in Q2 FY26 (sequential improvement from 13% decline in Q1 FY26)

    Mitigation: Centralized staff gaining experience and proficiency; process expected to improve.

    Potential extension of hospice moratorium on new CONsNear-term (next 60 days)

    Moratorium due to end in November, but could be extended.

    Mitigation: Focusing on acquisitions of existing providers (in service for 3+ years) in markets with barriers to entry.

    Increased program integrity oversight in hospiceFY27 and beyond

    Expected elevated degree of program integrity oversight, e.g., SSVI (service spend variation index)

    Mitigation: Focusing on quality metrics and maintaining compliance; no expectation of unbundling hospice benefit or material reimbursement changes.

    What to watch in Q3 FY26

    5

    Roto-Rooter water restoration average job revenue

    next quarter
    Currentdeclined 3.5%
    Targetcontinued improvement

    Why it matters

    Indicates the success of the centralized billing and collection model and its impact on Roto-Rooter's profitability.

    We anticipate that this challenge will continue to improve as the year progresses with centralized staff gaining experience and proficiency.

    Q&A highlights

    6

    How sustainable is VITAS's current level of growth, particularly with the 42-45% hospital admission mix, and what is the long-term ADC and revenue growth outlook?

    Management believes the current growth is very sustainable due to strategic management of KPIs and resources, allowing them to react to market changes. They expect to continue generating double-digit growth rates, similar to historical performance over 21 years.

    We absolutely believe it is very sustainable. We feel like the strategies we put in place and the KPI management associated with those strategies helps us much better understand how to react to market changes and adjust resources accordingly.

    asked by Ben Hendrix · answered by Joel Wherley

    2 min read6 chapters

    Detailed Narrative

    01

    VITAS Outperformance and Strategic Growth

    VITAS significantly exceeded expectations in Q2 FY26, driven by accelerated admissions from non-hospital preadmission locations and sustained hospital-based admissions. Admissions increased 9% year-over-year, leading to a 6.1% increase in average daily census (ADC) to over 24,000 patients. This performance allowed VITAS to add $8.9 million to its Medicare cap cushion in Florida and achieve higher-than-expected revenue growth and EBITDA margins, signaling a return to normalized growth patterns after managing the 2025 Medicare Cap issue.

    02

    Roto-Rooter Commercial Momentum and Water Restoration Improvements

    Roto-Rooter demonstrated positive operating momentum, with commercial revenue increasing 6.8% year-over-year. The commercial business manager program proved highly effective, driving a 13% revenue increase in branches where it was implemented. The centralization of water restoration billing and collections continued to yield benefits, resulting in a $1.3 million improvement in total write-offs and a reduction of approximately 20 employees. The average revenue per water restoration job also showed sequential improvement, declining only 3.5% compared to a 13% decline in the prior quarter.

    03

    Roto-Rooter Marketing Challenges and Lead Generation Strategy

    Roto-Rooter faced ongoing challenges with lead generation and customer acquisition costs. Total leads were down 1.6% year-over-year, with internet search leads declining 13.1%. Paid leads increased 7.3% and now constitute 59% of all leads, up from 54% in Q2 2025, leading to a $3.1 million increase in marketing spend. Management is actively working to minimize reliance on paid search by developing alternative lead generation strategies, such as commercial business managers and exploring app-based solutions, to stabilize marketing expenses.

    04

    Franchise Acquisitions and Long-Term Growth Opportunities

    Roto-Rooter continues to pursue strategic franchise acquisitions to expand its footprint. In Q2, the company purchased the South Texas territory, including Corpus Christi, for approximately $12 million. This acquisition is expected to contribute to growth in 2027 and beyond. Through the first half of 2026, Chemed spent an aggregate of $33.5 million repurchasing four franchises in strategically advantageous locations, indicating a sustained focus on consolidating its franchise network for future growth.

    05

    Hospice Growth Sustainability and Resource Management

    Management expressed confidence in the sustainability of VITAS's growth, attributing it to effective strategic management of resources and key performance indicators. The ability to balance hospital-based admissions (shorter length of stay) with community-based admissions (longer length of stay) is crucial for maintaining margin and cap cushion. The company also noted that its back-office SG&A costs are expected to grow at half the rate of revenue, providing leverage and supporting sustainable EBITDA margins in the long term.

    06

    Hospice Regulatory Environment and Future Outlook

    Chemed does not anticipate significant or material reimbursement changes to the current hospice structure, despite ongoing discussions around program integrity and various government reports. While a moratorium on new CONs influences growth in some states, it does not prevent acquisitions of existing providers. The company expects increased program integrity oversight, such as the SSVI, and a focus on quality metrics, but sees no immediate indication of unbundling the hospice benefit or major reimbursement shifts for 2027.

    AI-generated summary of the company’s earnings call. Not investment advice.